[1] 王礼宁,马勇,郑苏阳,等.蛇床子素对NFATc1基因表达及破骨细胞分化的影响[J].中华骨质疏松和骨矿盐疾病杂志,2018,11(5): 475-483.
[2] BOSE S, SARKAR N. Natural medicinal compounds in bone tissue engineering. Trends Biotechnol. 2020;38(4):404-417.
[3] 何家扬.骨愈灵胶囊治疗Colles骨折34例临床观察[J].新中医,2013, 45(9):61-62.
[4] 王晓军.骨愈灵胶囊治疗骨质疏松性桡骨远端骨折效果分析[J].航空航天医学杂志,2012,23(10):1229-1230.
[5] 胡南.骨愈灵胶囊对上肢骨折患者术后疼痛、肿胀、骨折愈合的影响[J].医药前沿,2015,5(14):155-156.
[6] 何郁泉.骨愈灵胶囊治疗骨质疏松症及各类型骨折临床疗效观察[C].骨质疏松研究与防治文集.1994.
[7] 刘继平.骨愈灵胶囊主要药效及毒理学研究[D].西安:陕西中医药大学, 2008.
[8] 丁桂芝,李榕,周勇.骨愈灵胶囊治疗骨质疏松症32例疗效观察[J].医药导报,1994,(5):212-213.
[9] 高武兴.骨愈灵胶囊治疗骨质疏松症68例临床疗效观察[J].内蒙古中医药,2013,32(27):19-20.
[10] 吴永光.骨愈灵胶囊治疗骨质疏松症临床疗效观察[J].湖北中医杂志, 2012,34(6):32.
[11] 孙静. 蛇床子素促成骨作用及代谢多态性研究[D].天津:天津医科大学, 2019.
[12] ZHAO Y, XU Y, ZHENG H, et al. QingYan formula extracts protect against postmenopausal osteoporosis in ovariectomized rat model via active ER-dependent MEK/ERK and PI3K/Akt signal pathways. J Ethnopharmacol. 2021;268:113644.
[13] NOGUCHI T, EBINA K, HIRAO M, et al. Apolipoprotein E plays crucial roles in maintaining bone mass by promoting osteoblast differentiation via ERK1/2 pathway and by suppressing osteoclast differentiation via c-Fos, NFATc1, and NF-κB pathway. Biochem Biophys Res Commun. 2018;503(2):644-650.
[14] ZHAO H, YANG Y, WANG Y, et al. MicroRNA-497-5p stimulates osteoblast differentiation through HMGA2-mediated JNK signaling pathway. J Orthop Surg Res. 2020;15(1):515.
[15] BROWN KK, HEITMEYER SA, HOOKFIN EB, et al. P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis. J Inflamm (Lond). 2008;5:22.
[16] JO YJ, LEE HI, KIM N, et al. Cinchonine inhibits osteoclast differentiation by regulating TAK1 and AKT, and promotes osteogenesis. J Cell Physiol. 2021; 236(3):1854-1865.
[17] KOT A, ZHONG ZA, ZHANG H, et al. Sex dimorphic regulation of osteoprogenitor progesterone in bone stromal cells. J Mol Endocrinol. 2017;59(4):351-363.
[18] MUKHERJEE A, LARSON EA, KLEIN RF, et al. Distinct actions of akt1 on skeletal architecture and function. PLoS One. 2014;9(3):e93040.
[19] MUKHERJEE A, ROTWEIN P. Selective signaling by Akt1 controls osteoblast differentiation and osteoblast-mediated osteoclast development. Mol Cell Biol. 2012;32(2):490-500.
[20] MUKHERJEE A, WILSON EM, ROTWEIN P. Selective signaling by Akt2 promotes bone morphogenetic protein 2-mediated osteoblast differentiation. Mol Cell Biol. 2010;30(4):1018-1027.
[21] AMJADI-MOHEB F, AKHAVAN-NIAKI H. Wnt signaling pathway in osteoporosis: Epigenetic regulation, interaction with other signaling pathways, and therapeutic promises. J Cell Physiol. 2019;234(9): 14641-14650.
[22] Liu Y, Wang X, Chang H, et al. Mongolian Medicine echinops prevented postmenopausal osteoporosis and induced ER/AKT/ERK pathway in BMSCs. Biosci Trends. 2018;12(3):275-281.
[23] 刘景陶,柳耀花.计算机分子模拟技术及人工智能在药物研发中的应用[J].科技创新与应用,2018(2):46-47.
[24] 刘景陶,刘映雪.分子对接在药物研发中的应用[J].科技创新与应用,2018(1):167-168.
[25] 叶小彤.基于生物信息学的中药蛋白质成分作用机制研究[D].北京:北京中医药大学,2017.
[26] WANACHEWIN O, POTHACHAROEN P, KONGTAWELERT P, et al. Inhibitory effects of sesamin on human osteoclastogenesis. Arch Pharm Res. 2017; 40(10):1186-1196.
[27] 李慧英,孟东方,阮志磊.骨碎补总黄酮对激素性股骨头坏死血钙、血磷及空骨陷窝率的影响[J].中华中医药杂志,2016,31(12): 5352-5354.
[28] 王永胜,胡菁菁,卢育南,等.骨碎补总黄酮对去势大鼠骨质疏松的防治作用[J].中国卫生标准管理,2020,11(9):94-95.
[29] KIM EK, CHOI EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta. 2010;1802(4):396-405.
[30] 陈建勇,王聪,王娟,等.MAPK信号通路研究进展[J].中国医药科学, 2011,1(8):32-34.
[31] YANG Y, FANG S. Small non-coding RNAs-based bone regulation and targeting therapeutic strategies. Mol Cell Endocrinol. 2017;456:16-35.
[32] XING LZ, NI HJ, WANG YL. Quercitrin attenuates osteoporosis in ovariectomized rats by regulating mitogen-activated protein kinase (MAPK) signaling pathways. Biomed Pharmacother. 2017;89:1136-1141.
[33] TAK PP, FIRESTEIN GS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest. 2001;107(1):7-11.
[34] AN Y, ZHANG H, WANG C, et al. Activation of ROS/MAPKs/NF-κB/NLRP3 and inhibition of efferocytosis in osteoclast-mediated diabetic osteoporosis. FASEB J. 2019;33(11):12515-12527.
[35] ONO K, HAN J. The p38 signal transduction pathway: activation and function. Cell Signal. 2000;12(1):1-13.
[36] BA P, DUAN X, FU G, et al. Differential effects of p38 and Erk1/2 on the chondrogenic and osteogenic differentiation of dental pulp stem cells. Mol Med Rep. 2017;16(1):63-68.
[37] XIAO L, ZHONG M, HUANG Y, et al. Puerarin alleviates osteoporosis in the ovariectomy-induced mice by suppressing osteoclastogenesis via inhibition of TRAF6/ROS-dependent MAPK/NF-κB signaling pathways. Aging (Albany NY). 2020;12(21):21706-21729.
[38] LEE JY, PARK SJ, KIM DA, et al. Muscle-derived lumican stimulates bone formation via integrin α2β1 and the downstream ERK signal. Front Cell Dev Biol. 2020;8:565826.
[39] JIN H , SHAO Z , WANG Q, et al. Sclareol prevents ovariectomy-induced bone loss in vivo and inhibits osteoclastogenesis in vitro via suppressing NF-κB and MAPK/ERK signaling pathways. Food Funct. 2019;10(10):6556-6567.
[40] WANG W, BAI J, ZHANG W, et al. Protective effects of punicalagin on osteoporosis by inhibiting osteoclastogenesis and inflammation via the nf-κb and mapk pathways. Front Pharmacol. 2020;11:696.
|